Rhabdomyosarcoma in the maxillary gingiva of a child patient

Komatsu, Yuko; Kawai, Tadashi; Miura, Shingo; Takeda, Yasunori; Yamada, Hiroyuki

doi:10.1093/jscr/rjab322

Cited by 2 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, the overall cure rates have improved significantly thanks to the multimodal therapies, including surgery, radiation therapy, and chemotherapeutics (with various combinations of vincristine, actinomycin D, cyclophosphamide, etoposide, irinotecan, or ifosfamide). We closely studied recent cases of different locations (paratesticular, prostate, biliary and uterine) of RMS and found surgical therapy is the key basis and significant treatment for a better prognosis of patients with RMS except with orbital rhabdomyosarcoma (19)(20)(21)(22)(23)(24). These available findings are consistent with our review.…”

Section: Discussionsupporting

confidence: 85%

Case Report: Pediatric Hepatic Rhabdomyosarcoma With Maximum Lifetime

Yang

et al. 2022

Front. Med.

View full text Add to dashboard Cite

Primary intrahepatic rhabdomyosarcoma is an extremely rare malignant tumor. Here, we describe a case of embryonal rhabdomyosarcoma of the liver in a 7-year-old boy without any symptoms. Serologically, the patient showed abnormal levels of serum tumor markers and liver function. Imaging revealed a large mass in the left lobe of the liver and no lesions elsewhere. At first, the patient was misdiagnosed by percutaneous liver biopsy as having clear cell sarcoma. However, the final diagnosis was established to be hepatic embryonal rhabdomyosarcoma based on postoperative histopathology and typical immunohistochemical staining, which was positive for desmin and myogenin. For treatment, the patient received two cycles of preoperative chemotherapy, prophylactic radiotherapy, and 13 cycles of combined postoperative chemotherapy. Routine follow-ups after all treatment conducted by imaging examinations showed no sign of recurrence or metastasis over 13 months, and the patient survives more than 38 months since initial diagnosis. To our knowledge, this patient is the first with hepatic rhabdomyosarcoma to receive neoadjuvant chemotherapy (preoperative chemotherapy) combined with relative comprehensive treatment and achieve a favorable result.

show abstract